Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 81 | ECE2022 | Next issue

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

Card image cap
The 24th European Congress of Endocrinology (ECE) and the Italian Society of Endocrinology look forward to welcoming you to Milan. ECE 2022 returns for a four day, six parallel session festival of endocrine science. You can join us In person in Milan, Italy OR Live @Home online!

Poster Presentations

Pituitary and Neuroendocrinology

ea0081p138 | Pituitary and Neuroendocrinology | ECE2022

Takayasu’s artheritis presenting as a large sellar mass with neurological and hypopituitarism manifestations

Galazzi Elena , Giancola Noemi , Citterio Valeria , Moro Mirella , Addobbati Laura , Avignone Sabrina , Capsoni Franco , Persani Luca

Introduction: Only one case of hypophysitis secondary to Takayasu’s artheritis (TKA) has been described so far. We report the second case of a TKA presenting with a massive sellar and cerebrovascular infiltration.Clinical case: A 52 years-old female was referred to endocrine outpatient clinics after a brain MRI performed for a 2-year history of headaches, dizziness and general discomfort. Past medical history included hypertension and aspecific symp...

ea0081p139 | Pituitary and Neuroendocrinology | ECE2022

Pituitary apoplexy in the aftermath of a SARS-CoV-2 infection: a case series from Amiens University Hospital

Balmain Joe , Al-Salameh Abdallah , Desailloud Rachel

Introduction: Since the outbreak of the COVID-19 pandemic, several cases of pituitary apoplexy following a SARS-CoV-2 infection have been described in several countries. Here, we describe a case series of pituitary apoplexy occurring in the aftermath of a SARS-CoV-2 infection to alert physicians about possible neuro-endocrinological damage caused by the virus that can lead to visual sequelae and hypopituitarism.Methods: We retrospectively identified all ...

ea0081p140 | Pituitary and Neuroendocrinology | ECE2022

Efficacy of lanreotide 120 mg primary therapy on tumor shrinkage and ophthalmologic symptoms in acromegaly after one month

Benderradji Hamza , Elise Vernotte , Ares Gustave Soto , Jean Philippe Woillez , Romain Perbet , Melodie-Anne Karnoub , Benoit Soudan , Arnaud Jannin , Assaker Richard , Luc Buee , Prevot Vincent , Claude-Alain Maurage , Pascal Pigny , Marie-Christine Vantyghem , Emilie Merlen , Cortet Rudelli Christine

Introduction: Few studies to date have attempted to evaluate the early efficacy of first-generation somatostatin analogs in somatotroph macroadenomas.Objective: To investigate the short-term efficacy of primary therapy with lanreotide 120 mg on tumor shrinkage and ophthalmologic symptoms in newly diagnosed patients with acromegaly.Design and patients: This single-center retrospective study included 21 patients who were newly diagno...

ea0081p141 | Pituitary and Neuroendocrinology | ECE2022

Bartter syndrome type I: a rare cause of polyuria-polydipsia syndrome with failure to thrive in a child

Barbacariu Ioana-Cristina , blesneac ilona-beatrice , Rosu Andreea , Protop Madalina , Munteanu Mihaela , Gorduza Eusebiu-Vlad , Preda Cristina

Introduction: Bartter syndrome (BS) is a rare autosomal recessive disorder, with an estimated prevalence of 1 in 1.000.000. It is characterized by a primary defect in sodium chloride reabsorption in the medullary thick ascending limb of Henle’s loop. Severe hypokalemia, metabolic alkalosis, hyponatremia, hypochloremia, hyperaldosteronism, and increased urinary loss of sodium, potassium, and chloride can raise the suspicion of BS, but genetic testing is required for a defi...

ea0081p142 | Pituitary and Neuroendocrinology | ECE2022

Chondrosarcoma of the cavernous sinus treated with postoperative proton radiation therapy: case report and endocrinological follow up after 36 months

Masi Davide , risi renata , balena angela , caputi alessandra , elena spoltore maria , rossetti rebecca , watanabe mikiko , Tozzi Rossella , Gangitano Elena , mariani stefania , Lenzi Andrea , gnessi lucio , lubrano carla

Case Summary: In May 2018, a 22-year-old man was admitted to the Emergency Room of Polyclinic Umberto I Hospital of Rome, because of progressive headaches and binocular diplopia. Brain MRI revealed a heterogeneous T1WI-hypointense and T2WI-hyperintense mass of 40x28x25 mm (CC, LL, AP) including calcification areas in the left paramedian region of the clivus invading the homolateral cavernous sinus. The patient underwent partial tumour resection via infratemporal approach and a...

ea0081p143 | Pituitary and Neuroendocrinology | ECE2022

Efficacy and safety of long-term high doses of cabergoline in prolactin secreting tumor

Bona Chiara , Prencipe Nunzia , Mazza Enrico , Maria Berton Alessandro , Bioletto Fabio , Varaldo Emanuele , Cuboni Daniela , Gottero Cristina , Gasco Valentina , Ghigo Ezio , Grottoli Silvia

Purpose: The aim of this study was to identify any predictive factors for need of high doses of cabergoline (CAB) in prolactinomas and to study any relationship between adverse events onset and CAB cumulative dose.Methods: Forty-two patients harboring resistant prolactinomas (High Dose group-HD; cabergoline dose ≥ 3.5 mg/week) were matched by gender, age and pituitary tumor diameter at diagnosis with subjects under standard doses (Standard Dose gro...

ea0081p144 | Pituitary and Neuroendocrinology | ECE2022

Gene expression profiling of subcutaneous adipose tissue reveals new biomarkers in active acromegaly

Maria Falch Camilla , Arlien-Soborg Mai C. , Dal Jakob , Sundaram Arvind , Michelsen Annika E. , Ueland Thor , Olsen Linn G. , Heck Ansgar , Bollerslev Jens , Jorgensen Jens Otto , Olarescu Cristina

Objective: Patients with acromegaly present increased insulin resistance despite reduced adipose tissue (AT) mass. Growth hormone (GH) stimulates lipolysis, but the role of AT as a metabolic factor in patients with acromegaly is still uncertain. Moreover, there is a need for better biomarkers of disease activity in acromegaly.Methods: RNA-sequencing was performed on paired subcutaneous AT (SAT) biopsies from patients (n=6) with active acromegaly...

ea0081p145 | Pituitary and Neuroendocrinology | ECE2022

The role of advanced glycation end products on vertebral fractures in patients with acromegaly

Melin Uygur Meliha , Dereli Yazıcı Dilek , Gogas Yavuz Dilek

Introduction: Acromegalic osteopathy is an emerging complication characterized by high risk for vertebral fractures (VFS), whereas bone mineral density (BMD) may not be useful to predict the risk. Recent studies have reported that increased advenced glycation end products (AGEs) are associated with bone fragility. We aimed to evaluate the relationship between AGEs and VFs in patients with acromegaly.Study design: Cross-sectionalPat...

ea0081p146 | Pituitary and Neuroendocrinology | ECE2022

Central Diabetes Insipidus, family report, molecular study, and its importance

Filipe Sa Luis , Sousa Rafaela , Villela Darine , Cavalcanti Thereza , Migliavacca Michele , Fontes Rosita , Guimaraes Marilia , Souza Micheline , Coelho Paula , Botelho Mariana , Nascimento Joao , Carvallo Mirna , Viveiros Pedro , Lourenco Jr Delmar , Naliato Erika , Violante Alice

Introduction: Central diabetes insipidus (CDI) occurs due to deficient secretion of arginine vasopressin (AVP) or antidiuretic hormone (ADH) by the posterior pituitary. It is a rare disease with an estimated prevalence of 1:25000. CDI can be acquired or congenital, secondary to malformation or genetics. Familial CDI (genetic inheritance) is mainly autosomal dominant. More than 80 mutations in the AVP gene have been described. In hereditary CDI, the age of onset is variable. Sy...

ea0081p147 | Pituitary and Neuroendocrinology | ECE2022

Are pre-operative intratumoral haemorrhages and post-operative bleeds sentinel indicators of ‘’silent’’ corticotroph adenomas?

Shaan Goonoo Mohummad , Bojoga Andreea , Sinha Saurabh , Debono Miguel

Background: Silent corticotroph adenomas (SCAs) are considered to be clinically silent and non-secreting but exhibit positive adrenocorticotropic hormone (ACTH) immunostaining. Whether, SCAs behave more aggressively than other non-functioning adenomas, remains controversial. We characterized our tertiary centre cohort of SCA patients, compared them to gonadotroph adenomas (GAs) and assessed for features predictive of recurrence.Objective: To compare char...

ea0081p148 | Pituitary and Neuroendocrinology | ECE2022

AZP-3813, a bicyclic 16-amino acid peptide antagonist of the human growth hormone receptor as a potential new treatment for acromegaly

Milano Stephane , Kurasaki Haruaki , Tomiyama Tatsuya , Reid Patrick , Jan Van der Lely Aart , Culler Michael D.

Medical treatment of acromegaly is based on either suppressing pituitary GH secretion or inhibiting GH action by preventing interaction with its receptor in order to suppress the elevated levels of IGF1. AZP-3813 is a 16-amino acid, bicyclic peptide antagonist of the GH receptor (GHR) derived from peptide sequences discovered using a unique, cell-free in vitro transcription-translation system screened against the human GHR, and that was optimized by rational design to increase...

ea0081p149 | Pituitary and Neuroendocrinology | ECE2022

Clinical aspects of pituitary tumors in patients with Multiple Endocrine Neoplasia Type 1: results from the preliminary study

Zgliczynski Stanislaw , Kochman Magdalena , Zgliczynski Wojciech , Bednarczuk Tomasz

Introduction: Multiple Endocrine Neoplasia Type 1 (MEN1) is a rare disease inherited in an autosomal dominant pattern, caused by mutations in the MEN1 gene. The cardinal components of this syndrome are: primary hyperparathyroidism (PHPT), gastroenteropancreatic neuroendocrine tumors (NETs) and pituitary tumors.Aim: The aim of the study was to evaluate clinical features of MEN1 patients under care of two teritiary centers in Warsaw, Poland with special fo...

ea0081p150 | Pituitary and Neuroendocrinology | ECE2022

Glucagon-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a double-blind randomized placebo-controlled study

Atila Cihan , Gaisl Odile , Vogt Deborah , Werlen Laura , Szinnai Gabor , Christ-Crain Mirjam

Background: The differential diagnosis between central diabetes insipidus and primary polydipsia is challenging. To date, the most reliable approaches are copeptin measurement after hypertonic saline infusion or arginine, which is a known growth hormone secretagogue but has recently been shown also to stimulate the neurohypophysis. Similar to arginine, glucagon is also known to stimulate growth hormone release, but its effect on the neurohypophysis and in the differential diag...

ea0081p151 | Pituitary and Neuroendocrinology | ECE2022

Sexual brain processing is enhanced by melanocortin-4 receptor agonism

Thurston Layla , Hunjan Tia , Mills Edouard , Wall Matt B , Ertl Natalie , Phylactou Maria , Muzi Beatrice , Patel Bijal , Alexander Emma , Suladze Sofiya , Modi Manish , Eng Pei , Bassett Paul , Abbara Ali , Goldmeier David , Comninos Alexander , Dhillo Waljit

Introduction: Hypoactive sexual desire disorder (HSDD) is characterized by a persistent deficiency of sexual fantasies and desire for sexual activity, causing marked distress or interpersonal difficulty. It is the most prevalent female sexual health problem worldwide, affecting approximately 1 in 10 women, but has limited treatment options despite its substantial health, social, and economic burden. Melanocortin-4 receptor (MC4R) agonists have emerged as a promising therapy fo...

ea0081p152 | Pituitary and Neuroendocrinology | ECE2022

Up to one third of the children with attention deficit with hyperactivity disorder (ADHD) may have an isolated and increased free-T3 level

Caci Herve , Caron Philippe

Introduction: Thyroid hormones are involved in the development of the fœtus and the child, and abnormal thyroid function is expected to play a role in neurodevelopmental disorders such as Attention Deficit with Hyperactivity Disorder (ADHD). The high prevalence of ADHD in patients with resistance to thyroid hormone syndrome is well documented but, surprisingly, the reported literature showed ambiguous results mostly suggesting that the thyroid function tests are normal in...

ea0081p153 | Pituitary and Neuroendocrinology | ECE2022

Subtype-specific pattern of white blood cell differential in endogenous Cushing’s syndrome

Detomas Mario , Altieri Barbara , Chifu Irina , Remde Hanna , Landwehr Laura-Sophie , Sbiera Silviu , Kroiss Matthias , Fassnacht Martin , Deutschbein Timo

Objective: Glucocorticoid excess impairs immune function, thereby predisposing patients with endogenous Cushing’s syndrome (CS) to infections. However, it is still not clear whether there is a CS-subtype specific pattern in white blood cell (WBC) and WBC differential (WBCD) count.Methods: Retrospective monocentric cohort study in patients with either overt endogenous CS or adrenal adenomas with autonomous cortisol secretion (ACS), with WBC and WBCD ...

ea0081p154 | Pituitary and Neuroendocrinology | ECE2022

Role of apparent strong ion difference in the differential diagnosis of thiazide associated hyponatremia

Potasso Laura , Refardt Julie , Monnerat Sophie , Winzeler Bettina , Christ-Crain Mirjam

Background: Differential diagnosis of hyponatremia is challenging, particularly for thiazide associated hyponatremia (TAH), as patients might have either volume depletion in need for fluid substitution or syndrome of inappropriate antidiuresis (SIAD)-like presentation requiring fluid restriction. Urine indices are of little utility, because they are influenced by thiazide therapy. Apparent strong ion difference (aSID) describes the relation between sodium, potassium and chlori...

ea0081p155 | Pituitary and Neuroendocrinology | ECE2022

Genetic subtype differences in relation to health problems among adults with Prader-Willi syndrome

Rosenberg Anna , Pellikaan Karlijn , Wellink Charlotte , Tellez Garcia Juan , van Abswoude Denise , van Zutven Laura , Bruggenwirth Hennie , Resnick James , Jan Van der Lely Aart , De Graaff Laura

Background: Prader-Willi syndrome (PWS) is a complex rare genetic disorder associated with hypothalamic dysfunction, pituitary hormone deficiencies, hyperphagia and (morbid) obesity. PWS is caused by loss of expression of paternally expressed genes on chromosome 15q11.2-q13. The most common genetic mechanisms leading to PWS are paternal deletion (DEL) and maternal uniparental disomy (mUPD). DELs can be subdivided in type 1 and (smaller) type 2 deletions (DEL-1, DEL-2). Most re...

ea0081p156 | Pituitary and Neuroendocrinology | ECE2022

Prevalence of comorbidities in a US adult population with growth hormone deficiency

Smith Alden , Manjelievskaia Janna , Komirenko Allison , Morrow Cynthia

Background: Adults with growth hormone deficiency (GHD) have increased central fat deposits, hypertriglyceridemia, and hyperglycaemia, with an increased risk of developing metabolic syndrome and cardiovascular disease, conditions that can lead to a diminished quality of life. This study analyzed comorbidities among adults with GHD in the US who had Medicaid or commercial health insurance.Methods: In this retrospective cohort study using IBM Marketscan Me...

ea0081p157 | Pituitary and Neuroendocrinology | ECE2022

Inverse relationship between il-6 and sodium levels in patients with COVID-19 and other respiratory tract infections

Monnerat Sophie , Atila Cihan , Bingisser Roland , Siegemund Martin , Lampart Maurin , Ruegg Marco , Zellweger Nuria , Osswald Stefan , Rentsch Katharina , Christ-Crain Mirjam , Twerenbold Raphael

Background: Hyponatremia is highly prevalent in patients with COVID-19. One of the most common causes of hyponatremia in these patients is the syndrome of inadequate antidiuresis (SIAD). Interleukin 6 (IL-6) is a key mediator of inflammation in COVID-19. We hypothesized that hyponatremia in COVID-19 is due to IL-6 mediated non-osmotic arginine vasopressin (AVP) secretion, and that the inverse association between IL-6 and plasma sodium concentration is stronger in COVID-19 comp...

ea0081p158 | Pituitary and Neuroendocrinology | ECE2022

Effect of growth hormone deficiency on serum high-sensitivity C-reactive protein levels in adult patients with non-functioning pituitary tumors

Seki Yasufumi , Takano Noriyoshi , Yamashita Kaoru , Bokuda Kanako , Sasaki Nobukazu , Ishikawa Toru , Kimura Miwa , Watanabe Satoshi , Watanabe Daisuke , Morimoto Satoshi , Ichihara Atsuhiro

Background: Growth hormone (GH) deficiency causes visceral obesity and fatty liver and increases cardiovascular event risks. Because serum high-sensitivity C-reactive protein (hs-CRP) levels, which has been used to estimate those risks, was reported to be decreased by GH supplementation therapy in GH deficient patients, it has been suggested that inflammatory processes might be activated in GH deficient state. However, the clinical factors associated with increased hs-CRP leve...

ea0081p159 | Pituitary and Neuroendocrinology | ECE2022

What is the relevance of he systematic use of gadolinium (Gd) during the MRI follow-up of non-functioning pituitary adenomas (NFPAs)?

Villemaire Axel , Mouly Celine , Solange Grunenwald , Adam Gilles , Darcourt Jean , Patsoura Sofia , Roques Margaux , Catalaa Isabelle , Fayolle Helio , Cognard Christophe , Sol Jean-Christophe , Caron Philippe , Fabrice Bonneville

Objective: To compare the performances of the coronal contrast-enhanced T1-weighted (ceT1-w) and T2-weighted (T2-w) sequences, for the diagnosis of progression during the MRI follow-up of NFPAs.Materials and methods: 106 patients who had at least two MRIs for the follow-up of NFPA were retrospectively included. The largest diameter of the adenomas was measured on coronal ceT1-w and separately on T2-w sequences for all the MRIs of the follow-up, and by 2 ...

ea0081p160 | Pituitary and Neuroendocrinology | ECE2022

Differences in pituitary apoplexy

Biagetti Betina , Isabel Sarria Estrada Silvana , Esteban Cordero-Asanza , Chaachou-Charradi Anas , Ng-Won Karelis , Cicuendez Lopez Ocana Marta , Hernandez-Hernandez Irene , Rojano Toimil Alba , Pilar Costa Forner M , Elena Martinez-Saez , Casteras Anna , Simo Canonge Rafael

Objective: Pituitary apoplexy (PA) is a rare, sometimes life-threatening clinical syndrome. However, some cases are subclinical (SPA), just revealed by MR performed during the follow-up of known pituitary adenomas or due to other conditions. Our aims were to describe the clinical characteristics and evolution of the patients with SPA compared with patients with acute PA (APA). We also compare the results of surgery vs conservative management in the APA group.<p class="abst...

ea0081p161 | Pituitary and Neuroendocrinology | ECE2022

The prevalence of metabolic syndrome in patients with hyperprolactinemia

Kim Eunheui , Im Myungsoo , Ryang Soree , Yi Wook , Kim Injoo

Objective: Hyperprolactinemia might be related to weight gain, metabolic syndrome, and insulin resistance. The aim of this study was to evaluate that patients with hyperprolactinemia were higher prevalence of metabolic syndrome than civilian population.Methods: From 1st Jan. 1998 to 17th Nov. 2017, 950 patients newly diagnosed hyperprolactinemia in Pusan National University Hospital, Pusan, South Korea, were selected to enroll in a study conducted on hyp...

ea0081p162 | Pituitary and Neuroendocrinology | ECE2022

Pituitary apoplexy: a retrospective study in a pituitary reference unit

Giron Giselle , Camara-Gomez Rosa , Hernandez Lorena , Lopez Regina , Vera Elena , Francisco Merino Torres Juan

Pituitary apoplexy (PA) is a rare syndrome that requires urgent assistance. It is due to ischemia or hemorrhage of pituitary tissue, almost always inside a pituitary tumor. PA may be the first manifestation of a neuroendocrine tumor or occur during follow up.Objective: To describe the characteristics of patients with PA treated in the Department of Endocrinology and Nutrition in the last 10 years and study the presence of possible risk factors for it.</p...

ea0081p163 | Pituitary and Neuroendocrinology | ECE2022

Clinical applicability of using SAGIT instrument and AcroQol in the management of patients with acromegaly

Herman Rok , Goricar Katja , Janez Andrej , Jensterle Mojca

Objective: We aimed to evaluate the ability of SAGIT Instrument and AcroQoL questionnaire to discriminate acromegaly control status and to correlate SAGIT scores to AcroQoL results in a cohort of the national referral centre.Methods: Cross-sectional study included 72 patients followed between 2000 and 2020. We retrospectively determined SAGIT score at the diagnosis. Based on the data from the most recent follow up and additional telephone interviews, we ...

ea0081p164 | Pituitary and Neuroendocrinology | ECE2022

Links between posterior pituitary activity, other endocrine abnormalities and psychometric profile in anorexia nervosa: a multimodal evaluation

Galusca Bogdan , Emmanuelle Doua Singoh Sandra , Germain Natacha , Mannel Merabet , Jerome Redoute , Boutet Claire , Catherine Massoubre

Introduction: Opioid system activity was found disturbed in several reward circuit areas in restrictive anorexia nervosa (AN) patients but also surprisingly at the pituitary level. However, the potential role of this specific abnormality of pituitary in AN physiopathology remains unclear or unknown.Objectives: The first aim was to find the exact pituitary location (posterior and/or anterior) of this disturbed opioid activity and then to study the link be...

ea0081p165 | Pituitary and Neuroendocrinology | ECE2022

Effects of the SGLT2-inhibitor empagliflozin in patients with chronic syndrome of inadequate antidiuresis (SIAD) - results of a double-blind, randomized, placebo-controlled, crossover trial

Refardt Julie , Imber Cornelia , Nobbenhuis Rianne , Clara Odilia Sailer , Haslbauer Aaron , Vogt Deborah , Berres Manfred , Winzeler Bettina , Bridenbaugh Stephanie , Mirjam Christ-Crain

Introduction: Hyponatremia is the most common electrolyte disorder and the syndrome of inappropriate antidiuresis (SIAD) is one of its main causes. However, treatment options for chronic SIAD-induced hyponatremia are inadequate. This is problematic because hyponatremia has been associated with neurocognitive deficits, although there is little data on its reversibility. We previously showed that the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin is a promising s...

ea0081p166 | Pituitary and Neuroendocrinology | ECE2022

Pasireotide imaging study: magnetic resonance imaging as a predictor of therapeutic response in acromegaly

Ruiz Sabina , Venegas Moreno Eva , Gil Joan , CAMARA ROSA , Biagetti Betina , Angeles Galvez Moreno Maria , Maraver Silvia , Gonzalez-Molero Inmaculada , Pico-Alfonso Antonio , Abellan Galiana Pablo , trincado pablo , Teresa Herrera Arranz Maria , Olvera Pilar , Xifra Villarroya Gemma , Bernabeu Ignacio , Azriel Mira Sharona , Garcia-GarciA-Doncel Lourdes , Jorda Mireia , Valassi Elena , Puig-Domingo Manel

Background: T2-weighted magnetic resonance imaging (MRI) signal has been recently linked with a better tumor response to pasireotide treatment in patients with acromegaly (ACRO). Our aim was to evaluate the prevalence of this radiological feature and its association to therapeutic outcomes in a large cohort of ACRO patients treated with pasireotide.Methods: A retrospective multicentre study was performed in 15 Spanish tertiary university hospitals includ...

ea0081p167 | Pituitary and Neuroendocrinology | ECE2022

Patient-reported outcomes (PRO) in adult growth hormone deficiency (aghd) for an improved patients’ management: results from the management of AGHD(MAGHD) study

Monzani Maria Laura , Pederzoli Simone , Bellelli Alessio , Magnani Elisa , Diazzi Chiara , Golinelli Caterina , Pacchioni Marco , Orsini Mirko , Rochira Vincenzo

Background: AGHD is a recognized clinical entity, but symptoms are quite nonspecific; the lack of objective tools able to measure patients’ health status remains the main barrier in clinical monitoring and treatment.Aim: The MAGHD Study aims improving AGHD patients’ management through a Smartphone app (MAGHDApp) and a fit-watch integrated with a software framework able to merge daily data of patients’ well-being and physical activity with ...

ea0081p168 | Pituitary and Neuroendocrinology | ECE2022

Impact of USP8 mutations on corticotroph tumor cells responsiveness to pasireotide

Peverelli Erika , Marra Giusy , Treppiedi Donatella , Di Muro Genesio , Esposito Emanuela , Maria Barbieri Anna , Catalano Rosa , Mangili Federica , Locatelli Marco , Lania Andrea , Ferrante Emanuele , Indirli Rita , Spada Anna , Arosio Maura , Mantovani Giovanna

Somatic mutations in the ubiquitin specific peptidase 8 (USP8) gene have been associated with higher levels of somatostatin (SS) receptor subtype 5 (SSTR5) in adrenocorticotroph hormone (ACTH)-secreting pituitary neuroendocrine tumors (PitNETs). However, a correlation between the USP8 mutational status and favorable responses to pasireotide, the somatostatin multi-receptor ligand acting especially on SSTR5, has not been investigated yet. Here, we studied the impact of USP8 mut...

ea0081p169 | Pituitary and Neuroendocrinology | ECE2022

Identification of a novel SSTR3 full agonist and its activity in non-functioning pituitary adenoma model

Modena Daniela , Luisa Moras Maria , Sandrone Giovanni , Stevenazzi Andrea , Vergani Barbara , Dasgupta Pooja , Kliewer Andrea , Gulde Sebastian , Schillmaier Mathias , Luque Raul M. , Schulz Stefan , Pellegata Natalia , Steinkuhler Christian

Non-functioning pituitary adenomas (NFPAs), mainly gonadotroph pituitary adenomas (GPAs), are the second most common type of PAs. Given the lack of symptoms secondary to hormone hypersecretion, NFPAs are often diagnosed when they cause mass effects. At this stage they are invasive (50% of cases), they cannot be completely resected and often recur. Despite their frequency, no standard of care drug treatment currently exists for these tumors. SSAs (somatostatin agonists) like oc...

ea0081p170 | Pituitary and Neuroendocrinology | ECE2022

Safety comparison of 40- vs 60- mg/day doses of oral octreotide capsules for treatment of acromegaly in the chiasma optimal trial

L. Samson Susan , Nachtigall Lisa B. , Fleseriu Maria , Molitch Mark E. , Giustina Andrea , Haviv Asi , Biermasz Nienke , Kennedy Laurence , Jensterle Mojca , Manning Patrick , Elenkova Atanaska , Melmed Shlomo , Strasburger Christian J.

Background: Oral octreotide capsules (OOC) are a treatment option for patients with acromegaly in the United States who have previously responded to injectable somatostatin receptor ligands (iSRLs, octreotide or lanreotide). In previous phase 3 studies, the safety of OOC was shown to be consistent with iSRLs, without dose-dependent adverse reactions. In the double-blind, placebo-controlled period (DPC) of the CHIASMA OPTIMAL trial (NCT03252353), patients were randomized to twi...

ea0081p171 | Pituitary and Neuroendocrinology | ECE2022

Efficacy of pasireotide LAR for acromegaly: a long-term real-world monocentric study

Zampetti Benedetta , Isabella Carioni Emanuela , Dalino Ciaramella Paolo , Grossrubatscher Erika , Dallabonzana Daniela , Attanasio Roberto , Cozzi Renato

Patients: Nineteen acromegalic patients (8 females, 21-69 years-old, with macroadenoma, microadenoma or no evidence of pituitary tumor in 15, 2, 2, respectively) resistant to first generation somatostatin analogs (FG-SA) at high doses and/or intolerant to pegvisomant were switched to pasireotide LAR (PasLAR). Eleven had persistent disease after neurosurgery and two had also undergone radiosurgery (12 and 24 months before starting PasLAR). Six complained of acromegalic headache...

ea0081p172 | Pituitary and Neuroendocrinology | ECE2022

Towards a pituitary apoplexy classification based on clinical presentation and patient journey

Guijt Mathijs , Zamanipoor Najafabadi Amir , Notting Irene , M Pereira Alberto , Verstegen Marco , Biermasz Nienke , van Furth Wouter , Claessen Kim

Purpose: The condition of pituitary apoplexy contains the clinical spectre from life-threatening emergency to a condition with chronic symptoms and self-limiting course, which partly determines diagnostic delay and management. Outcome evaluation of course and management of pituitary apoplexy is hampered by the diverse presentation of this condition and requires appraisal. This study aimed to describe the patient journey, clinical presentation and management of various types of...

ea0081p173 | Pituitary and Neuroendocrinology | ECE2022

The immune microenvironment landscape in pituitary tumors, genes and cells

Vela Patino Sandra , Isabel Salazar Ma. , Remba-Shapiroa Ilan , Pena-Martinez Eduardo , Silva-Roman Gloria , Andoneui-Elguera Sergio , Taniguchi-Ponciano Keiko , Bonifaz Laura , Aguilar-Flores Cristina , Mercado Moises , Marrero-Rodriguez Daniel

The tumor immune microenvironment is essential, it could influence a favorable or negative response against the tumor cells, and it has been related to therapy response and prognostic factors. Tumor infiltrating lymphocytes (TILs) plays an important role in the development, progression, and tumor control, thus presence of TILs could be related to disease-specific traits. The aim of the present work is to evaluate the expression of immune-related genes in forty-two pituitary ad...

ea0081p174 | Pituitary and Neuroendocrinology | ECE2022

The positive feedback exerted by mtor inhibitor everolimus in pituitary neuroendocrine tumoral cells is reverted by cabergoline co-treatment

Mangili Federica , Esposito Emanuela , Treppiedi Donatella , Catalano Rosa , Marra Giusy , Di Muro Genesio , Maria Barbieri Anna , Locatelli Marco , Gerardo Lania Andrea , Spada Anna , Arosio Maura , Mantovani Giovanna , Peverelli Erika

The mTOR inhibitor everolimus has been shown to display antimitotic effects on diverse neoplasms, including pituitary neuroendocrine tumors (PitNETs); however, its effect is reduced by an escape mechanism that increases AKT phosphorylation (P-AKT) leading to survival pathway activation. Dopamine receptor type 2 (DRD2) reduces p-AKT in some non-functioning PitNETs (NF-PitNETs) and in lactotrophs MMQ cells, through a α-arrestin 2-dependent mechanism. This study aim...

ea0081p175 | Pituitary and Neuroendocrinology | ECE2022

Low post-operative cortisol after TSS for pituitary surgery predicts short term but not long term remission

Karunakaran Vanitha , Okasha Mohamed , W Thomas Nick , Barazi Sinan , Maratos Eleni , C Whitelaw Benjamin , Gilbert Jackie , V Carroll Paul , Shapey Jonathan , J B Aylwin Simon

Background: It is generally accepted that a post-operative cortisol of <50 nmol/l is a good predictor of long-term remission following trans-sphenoidal surgery (TSS).Aim: We wished to determine the rate of late recurrence and need for consequent intervention in patients who had initial biochemical remission after TSS for pituitary dependent Cushing’s.Methods: We performed a retrospective analysis of our patients who underw...

ea0081p176 | Pituitary and Neuroendocrinology | ECE2022

Antagonist of growth hormone-releasing hormone (GHRH) inhibits SARS-CoV-2 Spike protein-induced inflammation in macrophages and PBMCs

Granato Giuseppina , Gesmundo Iacopo , Lopatina Tatiana , Felice Brizzi Maria , Victor Schally Andrew , Granata Riccarda

Macrophages play essential roles in the immune defence and their hyperactivation has been implicated in epithelial damage in acute respiratory distress syndrome (ARDS), commonly observed in severe COVID-19 patients. In these cells, SARS-CoV-2 spike (S) protein triggers aberrant production of pro-inflammatory cytokines like interleukin-1 beta (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), as well as reactive oxygen species (ROS) and matrix meta...

ea0081p177 | Pituitary and Neuroendocrinology | ECE2022

Use of corrected SUVmax as a prognostic indicator of response to PRRT

Opalinska Marta , Sowa-Staszczak Anna , Kania-Kuc Adrian , Al Maraih Ibraheem , Gilis-Januszewska Aleksandra , Hubalewska-Dydejczyk Alicja

Background: PRRT is an effective treatment option (especially for controlling disease progression)for disseminated neuroendocrine tumors (NETs), with good expression of the somatostatin receptors. Despite significant progress in NET personalized management, searching for novel predictive and prognostic factors of response to PRRT is crucial for more effective follow-up, better treatment choices leading to more favorable final outcome. Some recent studies indicate that the resp...

ea0081p178 | Pituitary and Neuroendocrinology | ECE2022

Metastatic pheochromocythoma and paragangliomas: clinical and follow-up characteristics in a reference unit

Giron Giselle , Isabel Del Olmo Garcia Maria , Segura Angel , Prado Stephan , Bello Pilar , Palasi Rosana , Luis Ponce Jose , Lopez Agullo Susana , Gomez-Elegido Tenes Lidia , Francisco Merino Torres Juan

Introduction: Pheochromocytomas(PCC) and paragangliomas(PGGLs) are rare neuroendocrine tumors. Management is very complex, this is why physicians involved in the management of these patients need to take into account not only clinical aspects but also genetics of these tumors. We present a group of patients diagnosed of metastatic PGG or PCC, their characteristics and long term follow-up.Methods and design: Descriptive and unicentric study that includes ...

ea0081p179 | Pituitary and Neuroendocrinology | ECE2022

Role of beta arrestins and G proteins in mediating DRD2 signaling in pituitary tumors

Esposito Emanuela , Mangili Federica , Di Muro Genesio , Maria Barbieri Anna , Treppiedi Donatella , arlati federico , Catalano Rosa , Marra Giusy , nozza emma , Arosio Maura , Mantovani Giovanna , Peverelli Erika

Dopamine receptor type 2 (DRD2) agonists (DA) are the first-choice treatment for prolactin (PRL)-secreting pituitary tumors, but poorly effective in non-functioning (NF)-PitNETs. Along with G protein-dependent signaling, DRD2 also mediates non-canonical beta-arrestin-dependent pathways, where reduction of AKT phosphorylation plays a leading role for the antiproliferative effect of DRD2 in pituitary tumors. Through UNC9994 and MLS1547, a beta-arrestin 2-biased and a G protein-b...

ea0081p396 | Pituitary and Neuroendocrinology | ECE2022

Precision medicine: new perspectives for the treatment of GH-secreting tumors - the miss study

Maria Berton Alessandro , Prencipe Nunzia , Bertero Luca , Corsico Marina , Cuboni Daniela , Baldi Marco , Bima Chiara , Bianchi Antonio , Mantovani Giovanna , Ferrau Francesco , SARTORATO PAOLA , Gagliardi Irene , Grottoli Silvia

Introduction: First-generation SRL (fg-SRL) represent the treatment of choice in acromegaly patients with post-neurosurgical adenomatous remnant and GH-hypersecretion. Anyway, approximately 60% of patients do not achieve adequate disease control. The main predictors of resistance include male sex, young age, invasiveness of the lesion and its hyperintensity on T2-weighted MRI scans; but also, SSTR2 expression, the cytokeratin pattern, Ki-67 and the presence of AIP gene mutatio...

ea0081p397 | Pituitary and Neuroendocrinology | ECE2022

The cut-off limits of GH response to GHRH + arginine test related to body mass index for the diagnosis of adult GH deficiency: do we need to review our diagnostic criteria?

Cuboni Daniela , Varaldo Emanuele , Bioletto Fabio , Maria Berton Alessandro , Bona Chiara , Prencipe Nunzia , Ghigo Ezio , Maccario Mauro , Grottoli Silvia , Gasco Valentina

Introduction: The diagnosis of GH deficiency (GHD) in adults is based on a reduced GH response to provocative tests. The proportion of patients with low GH response to provocative tests increases with the number of other pituitary hormone deficiencies and several studies involving panhypopituitary patients have shown that under certain circumstances GH stimulation tests may be unnecessary to diagnose GHD.Objective: Aim of this study was to re-evaluate th...

ea0081p398 | Pituitary and Neuroendocrinology | ECE2022

SARS-CoV-2 infection in acromegaly patients: case series

Bilha Stefana , Matei Anca , Cristiana Istrate Andra , Leustean Letitia , Christina Ungureanu Maria , Branisteanu Dumitru D. , Preda Cristina

Introduction: SARS-Cov-2 infection challenged the appropriate management of acromegaly, because of delayed or limited admissions and treatment. Despite lack of data regarding SARS-Cov-2 infection in acromegalic patients (only one case reported to date), increased susceptibility to infection and poor prognosis might be triggered by the associated metabolic, cardiovascular and respiratory comorbidities. We report a series of acromegaly patients with a positive PCR test at their ...

ea0081p399 | Pituitary and Neuroendocrinology | ECE2022

Familial neurohypophyseal diabetes insipidus: an extremely rare report of a family with a nonsense mutation in the arginine vasopressin gene

Ramalho Diogo , Serra-Caetano Joana , Cardoso Rita , Rosinha Patricia , Filipa Araujo Barbara , Rua Ines , Rodrigues Orlando , Dinis Isabel , Mirante Alice

Introduction: Familial neurohypophyseal diabetes insipidus (FNDI) is a rare form of central diabetes insipidus (CDI) characterized by childhood-onset progressive polydipsia and polyuria due to mutations in the arginine vasopressin-neurophysin II (AVP-NPII) gene.Case description: Two male siblings were referred at 1 month of age to exclude CDI owing to a family history of CDI in the father and paternal grandfather. The proband was the fa...

ea0081p400 | Pituitary and Neuroendocrinology | ECE2022

European Registries for Rare Endocrine Conditions (EuRRECa): results from the core registry on hypothalamic and pituitary conditions

Luisa Priego Zurita Ana , Appelman-Dijkstra Natasha , Biermasz Nienke , Bryce Jillian , Burman Pia , Castano Luis , Dattani Mehul , Dekkers Olaf M. , Fibbi Benedetta , Gan Hoong-Wei , Gaztambide Sonia , Haeusler Gabriele , Haufler Florentina , Katugampola Harshini , Helene Lasolle , L Muller Hermann , Raverot Gerald , Rica Itxaso , van Beuzekom Charlotte , Sumnik Zdenek , de Vries Friso , Zamanipoor Najafabadi Amir , Ahmed Faisal , M Pereira Alberto

Introduction: The European Registries for Rare Endocrine Conditions (EuRRECa) was created in collaboration with the European Reference Network on Rare Endocrine Conditions (Endo-ERN), the European Society for Paediatric Endocrinology and the European Society of Endocrinology to support the needs of the endocrine community. The Core Registry, one of its platforms, enables the collection of longitudinal patient and clinician reported outcomes. A module collecting aspects of the ...

ea0081p401 | Pituitary and Neuroendocrinology | ECE2022

Prevalence, type and evolution of autoimmune diseases with respect to hormone control in patients with cortisol, GH and prolactin hypersecretion

Guaraldi Federica , Zoli Matteo , Arvat Emanuela , De Martin Martina , Pecori Giraldi Francesca , Carla Scaroni , Gori Davide , GIORDANO Roberta , Grottoli Silvia , Ghigo Ezio , Asioli Sofia , Mazzatenta Diego

Background: In vitro and animal experiments have clearly demonstrated that excessive cortisol, GH and prolactin secretion, as well as dopamine agonists (D2As) and somatostatin analogs (SSAs), often prescribed for their treatment, affect the immune response and the onset/evolution of autoimmune diseases (AIDs) through direct and indirect complex mechanisms. Data from clinical studies are very scanty.Study aim: To assess the 1) distribution of AIDs accordi...

ea0081p402 | Pituitary and Neuroendocrinology | ECE2022

Central pontine myelinolysis: Case report

Gonzalez Lazaro Paloma , Contreras Pascual Cristina , Montalban Mendez Cristina , Moreno Tirado Antonio , Zhao Montero Benitez Maria , Jimenez Torrecilla Pedro

Introduction: Central pontine myelinolysis (CPM) is a rare and potentially life-threatening complication of a sudden rise in serum osmolality. Along with extrapontine myelinolysis, it is part of the osmotic demyelination syndrome (ODS). Known risk factors include severe hyponatremia, alcoholism, thiazide use, hypokalemia, and malnourishment.Case report: We report the case of a 31-year-old-male with history of alcohol and cannabis dependence, who had atte...

ea0081p403 | Pituitary and Neuroendocrinology | ECE2022

GH/IGF-I impact hepatic lipid accumulation in non-acromegalic individuals with and without non-alcoholic fatty liver disease

Fellinger Paul , Beiglboeck Hannes , Pfleger Lorenz , Smajis Sabina , Gajdosik Martin , Marculescu Rodrig , Vila Greisa , Winhofer Yvonne , Kautzky-Willer Alexandra , Krebs Michael , Krssak Martin , Wolf Peter

Background: Growth hormone (GH) plays an important role in modifying body composition. In acromegaly, a state of chronic GH/IGF-I excess, visceral and ectopic fat mass, especially in the liver, are significantly reduced. The aim of this study was to investigate the impact of GH/IGF-I on hepatocellular lipid content (HCL) and energy metabolism in a non-acromegalic cohort of patients with and without non-alcoholic fatty liver disease (NAFLD).Methods: We pe...

ea0081p404 | Pituitary and Neuroendocrinology | ECE2022

Change in androgens and adrenal hormones during long-term osilodrostat treatment in patients with Cushing’s disease: Results from the Phase III, prospective LINC 3 study

Pivonello Rosario , M.K. Biller Beverly , Akira Shimatsu , Newell-Price John , Tabarin Antoine , Vila Greisa , Piacentini Andrea , Pedroncelli Alberto , Fleseriu Maria

Introduction: Osilodrostat decreases cortisol production by inhibiting 11β-hydroxylase, increasing adrenal hormones above the blockade. Here, we describe these effects of osilodrostat and associated adverse events (AEs). The efficacy and safety of osilodrostat in patients with Cushing’s disease (CD) were confirmed in the published Phase III, prospective LINC 3 study (NCT02180217).Methods: 137 patients with CD (mUFC >1.5x upper limit of norm...

ea0081p405 | Pituitary and Neuroendocrinology | ECE2022

Impact of urinary and late-night salivary cortisol levels on clinical signs of hypercortisolism and quality of life in patients with Cushing’s disease treated with osilodrostat

Newell-Price John , Fleseriu Maria , Pivonello Rosario , Feelders Richard , Lacroix Andre , Auchus Richard , Piacentini Andrea , Pedroncelli Alberto , M.K. Biller Beverly

Background: 24-h mean urinary free cortisol (mUFC) and late-night salivary cortisol (LNSC) levels are complementary parameters recommended for screening and monitoring treatment response in patients with Cushing’s disease (CD). In the published core period of the Phase III LINC 3 study (NCT02180217), therapy with osilodrostat (potent oral 11β-hydroxylase inhibitor) produced rapid, sustained reductions in mUFC and LNSC alongside improvements in clinical signs of hyper...

ea0081p406 | Pituitary and Neuroendocrinology | ECE2022

GLP-1 receptor agonists stimulate growth hormone release

Reppo Ingrid , Heinla Keiu , Sedman Tuuli , Volke Vallo

The secretion of growth hormone (GH) is under the feedback control of numerous nutritional and endocrine factors. The most widely used endocrine dynamic tests used to diagnose GH deficiency, insulin hypoglycemia test, and glucagon test, are time-consuming and cumbersome both for patients and medical personnel. There is an unmet need for easier to conduct, shorter, and safer diagnostic tests. We and other groups have previously demonstrated that acute administration of glucagon...

ea0081p407 | Pituitary and Neuroendocrinology | ECE2022

Endoscopic surgery for acromegaly: results and predictors of outcome from a 22-year experience of a referral Pituitary Centre

Guaraldi Federica , Zoli Matteo , Gori Davide , Cavicchi Riccardo , Pasquini Ernesto , Sollini Giacomo , Asioli Sofia , Mazzatenta Diego

Background: Endoscopic surgery (ES) performed in Pituitary Centers of Excellence (PCOE) represents the gold standard treatment for GH-secreting adenomas. However, rate of cure greatly varies according to definition criteria, follow-up duration, various patient and adenoma features, and surgeon ability.Study aim: To assess short- (3 month) and long-term (≥1 year) outcome and identify predictors of ES, in a large and homogeneous cohort of acromegaly ...

ea0081p408 | Pituitary and Neuroendocrinology | ECE2022

Pituitary adenomas in the elderly may be hiding behind age-related comorbidities

Djurdjevic Sandra Pekic , Stojanovic Marko , Gacic Emilija Manojlovic , Doknic Mirjana , Miljic Dragana , Milojevic Toplica , Milicevic Mihailo , Stanimirovic Aleksandar , Banjalic Sandra , Jemuovic Zvezdana , Jovanovic Marija , Djurovic Marina Nikolic , Grujicic Danica , Popovic Vera , Petakov Milan

Background: Extended life expectancy and increase in neuroimaging availability, lead to increase in incidence of pituitary adenomas (PA) diagnosed after the age of 70. Recognition of PA in the elderly may be challenging and delayed due to symptoms overlapping with aging and comorbidities.Objective: To investigate character and presenting symptoms of PA in patients diagnosed after the age of 70.Methods: 105 patients (7.9%) with PA d...

ea0081p409 | Pituitary and Neuroendocrinology | ECE2022

Differences of clinical characteristics and treatment of sporadic and MEN-1 related insulinomas

Opalinska Marta , Gilis-Januszewska Aleksandra , Morawiec-Sławek Karolina , Rzepka Ewelina , Bogusławska Anna , Sowa Staszczak Anna , Hubalewska-Dydejczyk Alicja

Background: Although in most cases insulinomas are small and benign tumors, in about 4% they are malignant, mainly in course of inherited syndromes like MEN1, tubular sclerosis or neurofibromatosis type 1. While in case of benign tumors surgery is usually curative, the metastatic form brings difficulties in managing due to dissemination and the risk of recurring, life-threating, severe hypoglycemias. To elucidate the clinical differences between sporadic and MEN-1 linked insul...

ea0081p410 | Pituitary and Neuroendocrinology | ECE2022

Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with cushing syndrome

G. Moraitis Andreas , Custodio Joseph , Cristina Tudor Iulia

Background: Relacorilant is a highly selective glucocorticoid receptor (GR) modulator in development for the treatment of endogenous Cushing syndrome (CS). Unlike the GR antagonist mifepristone, relacorilant lacks affinity for the progesterone and other receptors. In a phase 2 study in patients with CS (Pivonello et al, 2021), relacorilant provided clinically meaningful changes in several cortisol-excess-related comorbidities, including hypertension and hyperglycemia,...

ea0081p411 | Pituitary and Neuroendocrinology | ECE2022

Independent injection vs healthcare-setting administration of somatostatin analogues: A systematic literature review

Luiz Boguszewski Cesar , Korbonits Marta , Artignan Audrey , Martin Garcia Almudena , Houchard Aude , Ribeiro-Oliveira Antonio , W de Herder Wouter

Background: A systematic literature review (SLR) was conducted to assess the use of independent injections (self/partner/home-administered) as an alternative to healthcare-setting injections for chronic diseases. The primary objective was to identify studies reporting on independent injection of somatostatin analogues (SSAs). Comparative evidence on independent injection of other medications was examined as a secondary objective.Methods: MEDLINE/Embase/t...

ea0081p412 | Pituitary and Neuroendocrinology | ECE2022

Sodium alterations impair the long-term prognosis of hospitalized patients with COVID-19 pneumonia: hospital readmissions and mortality rates after a 18-month follow-up

Martino Marianna , Aboud Nairus , Perrone Michele , Falcioni Paolo , Giancola Giulia , Ciarloni Alessandro , Salvio Gianmaria , Silvetti Francesca , Taccaliti Augusto , Arnaldi Giorgio

Background: Dysnatremia is common in hospitalized patients, often worsening the prognosis in pneumopathies and critical illnesses, such as COVID-19. Here, hyponatremia is an indicator of pulmonary involvement, while hypernatremia is associated with worse assistance outcomes, particularly when resulting from an overcorrected hyponatremia. Longer hospitalizations, readmissions after discharge and higher short- and long-term mortality rates have been observed in acute patients ex...

ea0081p413 | Pituitary and Neuroendocrinology | ECE2022

Osilodrostat provides sustained clinical benefits and improves health-related quality of life in patients with cushing’s disease: results from the Phase III LINC 4 study

Feelders Richard , Gadelha Monica , Bex Marie , Witek Przemysław , Belaya Zhanna , Yu Yerong , Turcu Adina F. , Heaney Anthony , Auchus Richard , Piacentini Andrea , Pedroncelli Alberto , Snyder Peter J.

Background: Cushing’s disease (CD) is associated with hypercortisolism-induced cardiovascular morbidity and mortality and impaired patient quality of life (QoL). We report long-term effects of osilodrostat (potent 11β-hydroxylase inhibitor) on cardiovascular/metabolic-related risk factors, physical features of hypercortisolism and QoL in CD patients following the core and extension phases of the LINC 4 study (NCT02697734).Methods: LINC 4 compri...

ea0081p414 | Pituitary and Neuroendocrinology | ECE2022

Predictive factors of somatostatin receptor ligand response in acromegaly – a prospective study

Diana Ilie Mirela , Tabarin Antoine , Vasiljevic Alexandre , Jean-Francois Bonneville , Moreau-Grange Lucile , Schillo Franck , Delemer Brigitte , Barlier Anne , Figarella-Branger Dominique , Bisot-Locard Segolene , Santos Alexandre , Chanson Philippe , Raverot Gerald

Context: Somatostatin receptor ligands (SRLs) are the cornerstone medical treatment of acromegaly, however many patients remain uncontrolled under SRLs. Well-established predictive markers of response are needed.Objective: We aimed to explore the relationship between responsiveness to SRLs, on one hand, and somatostatin (SST)2A and 5 receptor expression, adenoma granulation, and T2-weighted MRI signal intensity (T2WSI), on the other hand.<p class="ab...

ea0081p415 | Pituitary and Neuroendocrinology | ECE2022

Effects of somapacitan on glucose metabolism in adults with GH deficiency

Johannsson Gudmundur , MK Biller Beverly , Fukuoka Hidenori , Ho Ken , Hojby Rasmussen Michael , Nedjatian Navid , Svaerke Claus , CJ Yuen Kevin , Takahashi Yutaka

Somapacitan is a once-weekly, long-acting growth hormone (GH) derivative approved for the treatment of adult GH deficiency (AGHD). Our objective was to evaluate the effects of somapacitan on glucose metabolism compared with daily GH or placebo in patients with AGHD using data from three previously published phase 3 trials: REAL 1 (NCT02229851), REAL 2 (NCT02382939) and REAL Japan (NCT03075644). REAL 1 was a randomised, placebo-controlled (double-blind) and active-controlled (o...

ea0081p416 | Pituitary and Neuroendocrinology | ECE2022

Cabergoline monotherapy in acromegaly – a multicenter, retrospective, cohort study of non-irradiated patients using current criteria for disease control

A Urwyler Sandrine , Samperi Irene , Lithgow Kirstie , Mavilakandy Akash , Matheou Mike , Ayuk John , Bradley Karin , Pal Aparna , Reddy Narendra , Karavitaki Niki

Background: Dopamine agonists (DA) are included in the management algorithm of acromegaly. Studies on cabergoline monotherapy report IGF-1 normalisation in between 0% and 100% of the patients during treatment periods ranging between 2.6 and 24 months. However, in many of these studies, previous radiotherapy is a confounding factor. Furthermore, real world data applying the current disease control criteria (normal IGF-1 and GH<1 mg/l) are not available. The aim of this stud...

ea0081p417 | Pituitary and Neuroendocrinology | ECE2022

Terlipressin induced acute severe hyponatremia

Pla Peris Begona , Castro de la Vega Iciar , Roxana Padilla Segura Mayet , Serisuelo Meneu Esther , Abellan Galiana Pablo , Maravall Javier , Perez Naranjo Susana , Gonzalez Boillos Margarita , Angel Merchante Alfaro Agustin

Introduction: Terlipressin is a non-selective vasopressin analogue used in patients with decompensated cirrhosis, gastrointestinal haemorrhage or hepatorenal syndrome. It directly binds to V1 receptors improving circulatory volume by causing splanchnic vasoconstriction and portal hypertension inhibition, and has a full V2 receptor agonism in the collecting duct. In consequence, it increases reabsorption of water and can lead to a decrease in plasma osmolality and hyponatremia....

ea0081p418 | Pituitary and Neuroendocrinology | ECE2022

Is there a difference in clinical skills gained between healthcare professionals of high- and low and middle-income countries with online simulation-based learning?

Ali Anisah , Malhotra Kashish , Zhou Dengyi , Ogiliev Tamzin , Synn Cuen Pan Carina , Warmington Emily , Chen Wentin , Kaur Harjeet , Sheikh Jameela , Sakthivel Pavithra , Nirmal Rachel , Soran Vina , Abdi Zakee , Allison Isabel , Piya Simran , Evans Nia , Hanania Thia , Delson Dwi , Melson Eka , Davitadze Meri , Kempegowda Punith , Simulation Simba

Background: There is a differential clinical learning opportunity for healthcare professionals in low- and middle-income countries (LMICs) compared to high-income countries (HICs). Barriers to learning include cost, time and accessibility. Simulation via Instant Messaging - Birmingham Advance (SIMBA) is a free virtual simulation-based model aimed at improving clinicians’ professional development, without compromising patient safety. The study compared the impact of SIMBA ...

ea0081p419 | Pituitary and Neuroendocrinology | ECE2022

Obstructive sleep apnea syndrome (OSAS) in acromegaly: does the gender matter?

Pio Giacomo , Feola Tiziana , Rostomyan Liliya , Vitrani Giuseppe , Petrossians Patrick , Beckers Albert , Romigi Andrea , Jaffrain-Rea Marie-Lise

Obstructive sleep apnea syndrome (OSAS) is a frequent cardiovascular risk factor in acromegaly. We aimed to retrospectively evaluate sex-related differences in OSAS characteristics and indications of non-invasive ventilation.Patients and Methods: Thirty-nine adult patients (16 F, 23 M) from two European centers were studied by home sleep apnea test (HSAT) or polysomnography (PSG). OSA was defined by an apnea-hypopnea index (AHI) ≥5/h and analyzed a...

ea0081p420 | Pituitary and Neuroendocrinology | ECE2022

A rare posterior pituitary tumor with thyroid transcription factor-1 positivity

Aksoy Şeyma , burhan sebnem , Dilara Tekin Uzman Rukiye , Şuheda Hatipoğlu Esra

Introduction: A pituitary adenoma is directly assumed to originate from anterior pituitary. It is expected that pathologies of posterior hypophysis cause diabates insipitus (DI). However recently posterior pituitary tumors (PPTs) are also declared which are not associated with DI in contrast to what is expected. Rather they have a clinical and radiologic presentation akin to anterior pituitary adenomas. Differentiation of two conditions is mainly based on pathologic immunohyst...

ea0081p421 | Pituitary and Neuroendocrinology | ECE2022

Efficacy of methotrexate in the treatment of isolated, steroid-resistant sarcoidosis of the hypothalamic-pituitary system

Kuca Pawel , Wojciechowska-Luzniak Agnieszka , Dzalach Lukasz , Migda Anna , Zielinski Grzegorz , Maksymowicz Maria , Witek Przemyslaw

Isolated sarcoidosis of the hypothalamic-pituitary system is a very rare form of neurosarcoidosis. It usually leads to secondary damage to endocrine function, resulting in hypopituitarism and diabetes insipidus. A 32-year-old male patient with progressive deterioration of his general condition, weakness, polyuria, dizziness and visual field disturbances was admitted to the Department of Endocrinology for the diagnosis of a tumor in the hypothalamic-pituitary region. MRI showed...

ea0081p422 | Pituitary and Neuroendocrinology | ECE2022

Aberrant expression of clock genes in human gastric neuroendocrine tumors type 1

Karapanagioti Angeliki , Nasiri-Ansari Narjes , Daskalakis Kosmas , Vlachou Erasmia , Kyriakopoulos Georgios , Randeva Harpal , Kaltsas Gregory , Kassi Eva

Introduction: Gastric neuroendocrine tumors (GNET) are rare gastric neoplasms which are developed due to hypergastrinemia and enterochromaffin-like (ECL) cell hyperplasia. Although the effect of the circadian clock system disruption on tumorigenesis has been already studied in various malignancies and autoimmune diseases, the role of the peripheral clock system in the transition from ECL-cell hyperplasia to GNEN1 (Type 1 Gastric Neuroendocrine Neoplasms) remains unexplored.</p...

ea0081p423 | Pituitary and Neuroendocrinology | ECE2022

The diagnosis of vertebral fractures on routine chest radiography of acromegaly patients: a real-life study

Sardella Chiara , Urbani Claudio , MARCONCINI GIULIA , Cappellani Daniele , Manetti Luca , De Liperi Annalisa , Romei Chiara , Morganti Riccardo , Marcocci Claudio , Bogazzi Fausto

Objectives: The primary objective was to study the prevalence and the risk factors of vertebral fractures (VFs) in acromegaly patients either at diagnosis of acromegaly or during the follow-up. The role of routine chest radiography for detecting VFs in acromegaly was also evaluated.Design and methods: A retrospective cohort study was performed on 60 consecutive acromegaly patients, in a tertiary referral center. The presence of VFs was firstly evaluated ...

ea0081p424 | Pituitary and Neuroendocrinology | ECE2022

Assessment of quality of life in women with Sheehan syndrome

Salhi Salma , Oueslati Ibtissem , Grira Wafa , Chaker Fatma , Khessairi Nadia , Yazidi Meriem , Chihaoui Melika

Introduction: Sheehan syndrome represents a rare cause of hypopituitarism. It results from postpartum ischemic necrosis of the pituitary gland. Data evaluating the quality of life in women with Sheehan syndrome are scarce. The aim of this study was to assess the quality of life in patients with Sheehan syndrome and to determine its associated factors.Methods: A cross-sectional study including women with Sheehan syndrome was conducted in the department of...

ea0081p425 | Pituitary and Neuroendocrinology | ECE2022

In-hospital hyponatremia is associated with loss of independence at discharge among older patients

Hans Tanu , Singh Navjot , Jagan Jacob Jubbin

Context: Hyponatremia is a hormonal disorder of water metabolism encountered in 2% of community dwelling adults in America and in over 15-20% of hospitalized adults.1,2 Hyponatremia leads to increase in risk of falls, cognitive deficits, gait disturbances, loss of independence, prolongation of hospital stay and mortality among older patients admitted to hospitals.3 Objective: To determine in-hospital mortality among older patients ...

ea0081p426 | Pituitary and Neuroendocrinology | ECE2022

3P syndrome: pheochromocytoma, paraganglioma, pituitary adenoma

Havlinova Barbora , Gabalec Filip , Solař Miroslav , Horacek Jiri , Cap Jan

Neuroendocrine tumours, especially pheochromocytomas, paragangliomas and pituitary adenomas, are more common in younger patients in 3rd–5th decade of life. PitNETs are the most common intracranial tumours, while PHEO and PGL are rare. The hormonal activity, signs and symptoms of NET are variable. PGL, PHEO and PitNET in one patient remains an exceptional association. 72 cases of concomitant pituitary adenoma and PGL have been reported to date. The first record of a patien...

ea0081p427 | Pituitary and Neuroendocrinology | ECE2022

Long-term Tolvaptan therapy in the treatment of SIAD in Elderly- A case report with challenging cytochrome P 450 drug interactions

Madhurya Kethireddi Keerthi , Babu Parthasarathy Sathish

Background: Chronic SIAD with its disabling impact is challenging to manage in elderly patients as fluid restriction or demeclocycline often has a limited success. Tolvaptan is a novel selective antagonist of vasopressin receptor (V2R) which is safely used in patients with SIAD and other conditions with hypervolemia. We report a case of longest Tolvaptan use with significant challenges amongst our case series which we had previously publishedMethod: A Ca...

ea0081p428 | Pituitary and Neuroendocrinology | ECE2022

RNA profiling of human growth hormone-secreting and non-functioning pituitary adenomas reveals novel and differentially expressed immune related genes

Spiteri Emma Jayne , Formosa Robert , Paul Ebejer Jean , Paul Pace Nikolai , Gruppetta Mark , Saliba David , Vassallo Josanne

Pituitary neuroendocrine tumours (PitNETs) are broadly classified as non-functioning pituitary adenomas (NFPAs) and functional pituitary adenomas (FPAs) which include growth hormone secreting adenomas (GHPAs). Since the role of the immune system in PitNET pathogenesis is still poorly understood, we employed RNA-sequencing technology to unravel differentially expressed genes in GHPAs and NFPAs. Here we present an RNA-sequencing workflow of GHPAs (n=3) and NFPAs (n<...

ea0081p429 | Pituitary and Neuroendocrinology | ECE2022

Time from first symptoms to diagnosis in patients with pituitary adenomas

Follin Cecilia , Dahlgren Christina , Alkebro Caroline , Burman Pia , Dahlqvist Per , Hoybye Charlotte , Lindgren Margareta , Ragnarsson Oskar , Wik Helena , Warn Maria , Akerman Anna-Karin , Eden Engstrom Britt , Ekman Bertil , Forsgren Maria

Background: Subtle symptoms such as fatigue, weight gain and depression are commonly present for years in patients with pituitary adenoma (PA) before the diagnosis is made. A delayed diagnosis with risk of increased morbidity and mortality may be due to differences between patient-reported symptoms and symptoms reported in the patient’s medical record.Aim: To estimate diagnostic delay and investigate the concordance between patient-reported symptoms...

ea0081p430 | Pituitary and Neuroendocrinology | ECE2022

Psychological impact of Covid-19 national lockdown on patients with Cushing’s syndrome in Italy: a case-control study

Di Paola Nicola , Barbot Mattia , Ferrante Emanuele , Ferrau Francesco , Gatto Federico , Maria Paragliola Rosa , Reimondo Giuseppe , Arnaldi Giorgio , Guarnotta Valentina , Ferrigno Rosario , Simeoli Chiara , Mantovani Giovanna , Scaroni Carla , Iasevoli Felice , Colao Annamaria , Pivonello Rosario

During the spring of 2020, a national lockdown was adopted in Italy to prevent COVID-19 pandemic spread. Restrictive measures have been associated with impaired psychological outcome in the general population. As patients with Cushing’s Syndrome (CS), including Cushing’s disease (CD), adrenal CS (ACS), and ectopic CS (ECS), are reportedly associated with a higher prevalence of anxiety, stress susceptibility, depression, and maniac episodes, during both active disease...

ea0081p431 | Pituitary and Neuroendocrinology | ECE2022

Acromegaly and aging: a double hit against quality of life?

Gagliardi Irene , Chiloiro Sabrina , Vallillo Maria , Bondanelli Marta , Volpato Stefano , Giampietro Antonella , Bianchi Antonio , De Marinis Laura , Chiara Zatelli Maria , Rosaria Ambrosio Maria

Introduction: Acromegaly patients (ACRO) show increased morbidity that affects health and quality of life (QoL). Elderly ACRO are going to increase in the next few years, but evidence regarding their management is lacking.Aim: To evaluate physical, functional and cognitive performances of elderly ACRO and the relationship with QoL.Methods: Multicenter case-control study conducted on 42 older ACRO (≥ 65 years) compared to an a...

ea0081p432 | Pituitary and Neuroendocrinology | ECE2022

A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly

Fleseriu Maria , Zhang Zhaoyun , Hanman Kate , Haria Keval , Houchard Aude , Khawaja Sheila , Ribeiro-Oliveira Antonio , Gadelha Monica

Background: Acromegaly is a rare disorder characterized by excess growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Extended dosing intervals (EDIs) of pharmacological treatments may reduce patient burden and costs compared with standard dosing. This systematic literature review (SLR) investigated treatment of acromegaly at EDIs.Methods: MEDLINE/Embase/the Cochrane Library (2001–June 2021) and key congresses (2018–2021) were searche...

ea0081p433 | Pituitary and Neuroendocrinology | ECE2022

Gene therapy of growth hormone resistant dwarfism in the laron mouse model – comparison of two doses

Chuan Sia Kian , Uin Gan Shu , Humairah Mohd Rodhi Siti , Kopchick John J. , Waters Michael J. , Onn Lee Kok

Growth hormone receptor (GHR) defective Laron Syndrome (LS) has been treated with daily subcutaneous recombinant insulin-like-growth factor 1 (IGF1) injections lasting many years. We have reported the results of treatment of 4-5 week old Laron dwarf mice (GHR-/-) with a single injection of an adeno-associated virus vector with a murine GHR (AAV-GHR) and a liver specific promoter at a dose of 4 × 1010 vector genome per mouse (Sia et al, Gene Therapy 202...

ea0081p434 | Pituitary and Neuroendocrinology | ECE2022

Recovery of pituitary dysfunction following surgery and radiotherapy in non-functioning pituitary macroadenomas

Hussein Ziad , J Marcus Hani , Grieve Joan , Dorward Neil , Bouloux Peirre , Baldeweg Stephanie

Background: Hypopituitarism is often part of the presenting clinical manifestation for patients with non-functioning pituitary macroadenomas (NFPMs). Rate of recovery of hypothalamic-pituitary endocrine axes following therapy is uncertain with no clear predictive factors.Aims: The aim of this study was to assess the degree of hypopituitarism recovery following surgery and radiotherapy in patients with NFPMs. Methods: All patients t...

ea0081p435 | Pituitary and Neuroendocrinology | ECE2022

Liver steatosis in an in vivo model of hyponatremia secondary to SIAD

Marroncini Giada , Naldi Laura , Ancheschi Cecilia , Fibbi Benedetta , Peri Alessandro

Hyponatremia is the most frequent electrolytic disorder in clinical practice. It is estimated that in about 50% of cases hyponatremia is secondary to the syndrome of inappropriate antidiuresis (SIAD). Hyponatremia is associated with a worse outcome and with increased mortality in several diseases, including cancer. In vitro and in vivo evidence shows that low [Na+ ] is associated with neurological and extra-neurological alterations, which include f...

ea0081p436 | Pituitary and Neuroendocrinology | ECE2022

Growth hormone-releasing hormone (GHRH) promotes survival and proliferation of neural stem cells and reduces amyloid-β-induced toxicity

Pedrolli Francesca , Banfi Dana , Gesmundo Iacopo , Guglielmotto Michela , Tamagno Elena , Schally Andrew V. , Ghigo Ezio , Granata Riccarda

Neurogenesis, the process by which new neurons are generated from precursors, persists in discrete regions of the adult hippocampus. The hippocampus is critical for learning and memory and is the main target of Alzheimer’s Disease (AD), which causes massive neuronal death, reduction in neurogenesis, and impairment in cognitive functions. Therefore, preventing neuronal loss or increasing the production of new neurons may represent a potential therapeutic strategy to reduce...

ea0081p437 | Pituitary and Neuroendocrinology | ECE2022

The screening and management of diabetes mellitus type 2 in patients with acromegaly- a tertiary centre service evaluation

Gray Harry , Witczak Justyna

Introduction: Acromegaly is the result of chronic growth hormone (GH) excess, which leads to decreased insulin sensitivity and increased glucose production, to the extent that the impaired blood glucose regulation (IGR) can be recognised as Type 2 Diabetes Mellitus (T2DM). This project looked to identify whether patients were adequately screened or identified as having T2DM on diagnosis of acromegaly. The secondary aim was to determine whether acromegaly treatment affected gly...

ea0081p652 | Pituitary and Neuroendocrinology | ECE2022

Thinking horses, finding zebras: a rare case report of a giant cell tumor of the skull in a pediatric patient

Popa Viviana , Florescu Alexandru , Preda Cristina

Giant cell tumors are rare, benign but aggressive and locally invasive tumors that usually affect the long bones in the limbs, typically presenting during the 3rd or 4th decade of life. Giant cell tumors of the skull are exceedingly rare, and less than 150 cases have been reported to date, of which less than 10 were described in the pediatric population. Here, we present the case of a 14 year old female that progressively developed severe headaches, blurr...

ea0081p653 | Pituitary and Neuroendocrinology | ECE2022

Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma

Rudman Yaron , Duskin-Bitan Hadar , Masri-Iraqi Hiba , Akirov Amit , Shimon Ilan

Objective: To study the baseline characteristics predicting hypogonadotropic hypogonadism (HH) persistence in men with macroprolactinoma following medical treatment with cabergoline.Design: Retrospective cohort study conducted in a tertiary pituitary center.Methods: Male patients diagnosed with macroprolactinoma and HH that received cabergoline treatment with subsequent prolactin normalization were included: men that achieved eugon...

ea0081p654 | Pituitary and Neuroendocrinology | ECE2022

Pre and post-surgical pituitary dysfunction increase the risk of mortality in patients with non-functioning pituitary tumors: A long-term cohort study

Beyhart Arturo , Mariaca Karla , Salva-Crespi Valeria , Diaz Catalan Daniela , Aldecoa Iban , L Olondo Maria , Sanchez-Dalmau Bernardo , Alobid Isam , Halperin Irene , Mora Mireia , Ensenat Joaquim , Alexandra Hanzu Felicia

Background: Long-term studies evaluating mortality in patients with non-functioning (NF) pituitary tumors (PitNets) are limited, although standardized mortality ratios (SMR) in these patients are reported to be higher than that of general population. There is also no agreement on predictive factors associated to the increased mortality apart from age at diagnosis and glucocorticoid substitution therapy dose.Objective: To assess long-term mortality and as...

ea0081p655 | Pituitary and Neuroendocrinology | ECE2022

Congenital combined pituitary hormone deficiency associated with primary ovarian insufficiency: a case report

terzi Ameni , Khessairi Nadia , mouelhi yasmine , Chaker Fatma , Chihaoui Melika

Introduction: Congenital combined pituitary hormone deficiency (CCPHD) is a rare disorder characterized by an impaired production of two or more hormones of the anterior pituitary gland. It is linked to different genetic mutations and requires an early diagnosis to prevent burdensome developmental consequences. Primary ovarian insufficiency, disparately is the depletion of ovarian function with loss of functional primordial follicles before the age of 40 years due to multiple ...

ea0081p656 | Pituitary and Neuroendocrinology | ECE2022

Insulin resistance, glucose and lipid metabolism in patients with PROP 1 mutation –single center, long term observation

Kluczyński Łukasz , Partyński Bartosz , Rogoziński Damian , Bogusławska Anna , Zygmunt-Gorska Agata , Wojcik Małgorzata , Starzyk Jerzy , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Introduction: A mutation in the PROP-1 gene is a rare cause of childhood-onset hypopituitarism. Patients with the disorder usually present with multiple pituitary hormone deficits. The pattern of development and the course of insufficiencies of individual axes remain unclear and affect patients metabolic status. Growth hormone therapy and substitution of other hormones may influence on glucose and lipid metabolism as well. Aim: To characterize the carboh...

ea0081p657 | Pituitary and Neuroendocrinology | ECE2022

Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment

C. Arlien-Soborg Mai , Alle Madsen Michael , Dal Jakob , Krusenstjerna-Hafstrom Thomas , Ringgaard Steffen , Skou Nickolaj , Lyng Hogild Morten , Otto Jorgensen Jens

Background: Insulin resistance as part of the metabolic syndrome is associated with ectopic lipid deposition. Growth hormone (GH) status also modulates ectopic lipid accumulation but how this associates with insulin resistance in patients with GH disorders is not well established.Aim: To study body composition, ectopic lipid deposition and insulin sensitivity in acromegaly and adult GH-deficiency before and after treatment.Subjects...

ea0081p658 | Pituitary and Neuroendocrinology | ECE2022

The diagnosis of recurrence during postoperative follow-up of Cushing’s disease

Barbot Mattia , Mondin Alessandro , Ceccato Filippo , Mazzeo Pierluigi , Lazzara Martina , Regazzo Daniela , Scaroni Carla

Introduction: Transsphenoidal surgery (TSS) is the first-choice treatment in Cushing’s disease (CD) with an immediate success rate of 70-80%. Unfortunately, due to the high rate of post-operative recurrences, CD patients require life-long surveillance. However, there is no consensus on how to follow these patients after TSS to early diagnose relapses. The aim of the study was to find reliable predictors of recurrence after neurosurgery in CD.Materia...

ea0081p659 | Pituitary and Neuroendocrinology | ECE2022

Evaluation of copeptin levels during glucagon stimulation test in children with suspected growth hormone deficiency

Ferrante Emanuele , Giacchetti Federico , Indirli Rita , Profka Eriselda , Rodari Giulia , Giavoli Claudia , Mantovani Giovanna , Arosio Maura

Introduction: Glucagon stimulation test is one of the recommended growth hormone provocation tests for diagnosing growth hormone deficiency in children. In adult patients, recent data showed that glucagon administration is able to stimulate the release of copeptin, the stable C-terminal glycopeptide of the AVP prohormone whose evaluation during hypertonic saline infusion represents the gold standard for the differential diagnosis of polyuria/polydipsia. However, similar data o...

ea0081p660 | Pituitary and Neuroendocrinology | ECE2022

Soluble alpha klotho in adult patients with growth hormone deficiency

Ribeiro de Oliveira Longo Schweizer Junia , Schilbach Katharina , Haenelt Michael , Gagliardo Anica , Stormann Sylvere , Schopohl Jochen , Bidlingmaier Martin

Background: We recently have shown a close association of high concentrations of soluble alpha klotho (sαKL) to disease activity in acromegaly. Small pilot studies suggested that sαKL concentrations might be reduced in GH deficiency (GHD) and increase after recombinant human GH (rhGH) therapy. Our aim was to evaluate the potential of sαKL as a biomarker in GHD.Methods: We evaluated sαKL in comparison to the classical biomarkers GH, IG...

ea0081p661 | Pituitary and Neuroendocrinology | ECE2022

Metyrapone vs osilodrostat in the short-term therapy of endogenous Cushing’s syndrome: results from a retrospective single center analysis

Detomas Mario , Altieri Barbara , Deutschbein Timo , Fassnacht Martin , Dischinger Ulrich

Background: Although surgery is considered the first-line treatment for patients with endogenous Cushing’s syndrome (CS), medical therapy is often required to control severe hypercortisolism. Metyrapone and osilodrostat are inhibitors of 11β-hydroxylase that have not been directly compared yet.Methods: Retrospective analysis of patients with adrenocorticotropin (ACTH)-dependent and ACTH-independent CS treated with metyrapone or osilodrostat (as...

ea0081p662 | Pituitary and Neuroendocrinology | ECE2022

Inferior petrosal sinus sampling for pituitary neuroendocrine tumors localization in cushing’s disease

Moreno-Moreno Paloma , Rosa Alhambra Exposito Ma , Rebollo-Roman Angel , Herrera-Martinez Aura D. , Angeles Galvez-Moreno Maria

Objective: Cushing’s disease (CD) is the most common cause of hypercortisolism after iatrogenic origin, it represents approximately 70% of patients with endogenous Cushing’s syndrome (CS) and ectopic ACTH secretion (10%). CD is caused by a corticotropin-secreting pituitary neuroendocrine tumor (ACTH-secreting Pit-NETs), 95% of cases as a microadenoma. In ACTH-dependent CS, differential diagnosis between CD and ectopic CS must be established. 40% of CD cases, any tumo...

ea0081p663 | Pituitary and Neuroendocrinology | ECE2022

GH-secreting pituitary adenoma: dura mater invasion is not a predictor of acromegaly persistence after trans-sphenoidal surgery

Prencipe Nunzia , Diperna Giuseppe , MARIA BERTON ALESSANDRO , Baldassarre Bianca , Bona Chiara , De Marco Raffaele , Bioletto Fabio , Grottoli Silvia , Zenga Francesco

Background: Despite the benign nature of pituitary adenomas, microscopic examination of surgical specimens showed that dural invasion occurs in about 42-85% of cases. No studies about dura mater invasion were conducted specifically in acromegaly, so the aim of the present study was to evaluate the relationship between histologically verified dural invasion and the “aggressiveness” features of GH-secreting adenomas.Methods: A prospective study i...

ea0081p664 | Pituitary and Neuroendocrinology | ECE2022

Impact of COVID-19 lockdown in patients with acromegaly: an Italian multicenter experience

Pirchio Rosa , Simona Auriemma Renata , Cambria Valeria , Gatto Federico , Carosi Giulia , Ragonese Marta , Guarnotta Valentina , Ceccato Filippo , Cozzolino Alessia , Mongioi Laura , Prencipe Nunzia , Nista Federica , Del Sindaco Giulia , Calogero Aldo , Isidori Andrea , Scaroni Carla , Giordano Carla , Ferrau Francesco , Mantovani Giovanna , Ferone Diego , Grottoli Silvia , Iasevoli Felice , Colao Annamaria , Pivonello Rosario

Over the last two years, COVID-19 outbreak and lockdown have exerted a remarkable psychological burden in the general population. Such an impact is supposed to be even worse in acromegaly, known to induce a severe psychological impairment due to its somatic disfigurements and systemic comorbidities. The current observational study aimed at investigating the impact of COVID-19 outbreak and lockdown on psychological health in acromegalic patients as compared to non-acromegalic h...

ea0081p665 | Pituitary and Neuroendocrinology | ECE2022

Long-term follow up after remission of Cushing’s disease - experience of a single centre

Popovic Bojana , Ognjanovic Sanja , Ilic Dusan , Elezovic Valentina , Opalic Milica , Radic Lena , Milicevic Mihailo , Macut Djuro P.

Introduction: Chronic endogenous hypercortisolism in Cushing’s syndrome imposes a great clinical burden of comorbidities, some of which might persist even after disease remission. Our aim was to analyze factors that predict long-term comorbidities after surgical remission of Cushing’s disease (CD).Subjects and methods: We retrospectively analyzed 37 patents (91.9% females) aged 39.5±13.9 years (10-70) with diagnosed CD, treated in our inst...

ea0081p666 | Pituitary and Neuroendocrinology | ECE2022

Inferior petrosal sinus sampling in differential diagnosis of adrenocorticotropic hormone (ACTH)-dependent cushing’s syndrome: a tertiary centre experience

Araujo Catia , Martins Ferreira Mafalda , Reis Guiomar Joana , Moreno Carolina , oliveira patricia , Baptista Carla , Gomes Leonor , rodrigues dircea , Paiva Isabel

Introduction: Inferior petrosal sinus sampling (IPSS) has been considered to be the gold standard for differential diagnosis of Cushing’s Disease (CD) and ectopic ACTH secretion (EAS).Aim: To describe the experience of our centre in performing IPSS, its safety and efficacy; assess remission rates from transphenoidal surgery and clinical course; approach to the difficulty in the etiological diagnosis of ACTH-dependent Cushing’s Syndrome.<p c...

ea0081p667 | Pituitary and Neuroendocrinology | ECE2022

Pituitary adenoma in multiple endocrine neoplasia type 1 (MEN1) syndrome: a single-center study

Modica Roberta , Liccardi Alessia , Minotta Roberto , Cannavale Giuseppe , Benevento Elio , Colao Annamaria

Background: Multiple endocrine neoplasia type 1 (MEN1), is an autosomal dominant inherited disorder with high penentrance, characterized by the onset of multiple tumors, mainly in parathyroid, pituitary gland and gastroenteropancreatic tract. During the course of the disease pituitary adenomas (PA) occur in 20-65%, rarely as first clinical manifestation, and are often described as larger, more aggressive, and more resistant to conventional therapy than their sporadic counterpa...

ea0081p668 | Pituitary and Neuroendocrinology | ECE2022

Ultrasound of the median nerve in acromegalic patients : changes at 1 year follow up

Sagova Ivana , Pavai Dušan , Mokaň Marian , Vaňuga Peter

Background: The aim of our study was to asses changes in the cross sectional area (CSA) of the median nerve by ultrasound in newly diagnosed acromegalic patients 1 year after treatment of acromegaly (transsphenoidal surgery, somatostatine analogues).Patients and methods: The study included 30 newly diagnosed acromegalic patients (18 females and 12 males) and 30 healthy controls (18 females and 12 males) matched for age, gender and body mass index. Clinic...

ea0081p669 | Pituitary and Neuroendocrinology | ECE2022

From silent to carcinoma: the genomic alterations landscape of whole spectrum macroadenoma corticotrope pituitary tumors and carcinoma

Taniguchi Keiko , Andonegui-Elguera Sergio , Elena Silva Roman Gloria , Pena-Martinez Eduardo , Vela Patino Sandra , Remba-Shapiro Ilan , Mercado Moises , Marrero-Rodriguez Daniel

Corticotrope cells give arise to utmost aggressive and to very rare pituitary neoplasias, including pituitary carcinomas, Crooke’s cell adenomas (CCA), clinically non-functioning silent corticotrope adenomas (SCA) and the Cushing-provoking pituitary adenomas (CD). The molecular etiopathogenesis of these tumors are still poorly understood. Therefore, we carried out whole exome sequencing to better understand the full genomic landscape single nucleotide variants and copy nu...

ea0081p671 | Pituitary and Neuroendocrinology | ECE2022

Targeting invasive pituitary adenomas: in vitro studies and in vivo investigations in a murine model of invasive pituitary tumors obtained by orthotopic pituitary GC cells injection

Chasseloup Fanny , Lefevre Etienne , Dormoy Alexandre , Ladurelle Nataly , Mignot Tiphaine , Janot Clement , Hage Mirella , Viengchareun Say , Zizzari Philippe , Chanson Philippe , Buchfelder Michael , Kamenicky Peter

Context: Surgical removal is the primary treatment option for pituitary adenomas. However, pituitary surgery is frequently incomplete because of invasion of extrasellar cerebral structures, notably, of the cavernous sinus. Our objective was to study the molecular basis of the cavernous sinus invasion by pituitary adenomas.Methods: We analyzed a tissue collection of 19 invasive pituitary adenomas with a sample from the intrasellar portion and a sample fro...

ea0081p672 | Pituitary and Neuroendocrinology | ECE2022

The role of HIF-1α and vegfa polymorphism (G634C) in the development of the aggressive pituitary adenomas

Khalimova Zamira , Azimova Ozoda

Introduction: Although pituitary adenomas are considered benign, some have invasive growth, which is one indicator of aggressiveness. Early prognostic markers of aggressiveness may influence the quality of life improvement in patients with aggressive pituitary adenomasObjectives: To study the clinical-immunological, molecular-genetic aspects of aggressive pituitary adenomas and to develop new approaches to early diagnosis and treatment.<p class="abst...

ea0081p673 | Pituitary and Neuroendocrinology | ECE2022

Transition in endocrinology: predictors of drop-out in a heterogeneous population during long-term follow-up

Romanisio Martina , Brasili Sara , Daffara Tommaso , Ferrero Alice , Vimercati Davide , Pizzolitto Francesca , Pitino Rosa , Luigi Maria Mollero Edoardo , Zavattaro Marco , Bellone Simonetta , Caputo Marina , Aimaretti Gianluca , Prodam Flavia

Aim: To evaluate: 1) clinical and epidemiological characteristics of outpatients transitioned from Pediatrics Endocrine (PED) to Adult Endocrine Department (AED) in a tertiary Centre; 2) transition process characteristics, and predictive factors of drop-out.Patients and methods: Demographic, clinical, and transition features of 170 consecutive patients with paediatric onset of chronic endocrine or metabolic disease (excluded type 1 diabetes) who transiti...

ea0081p674 | Pituitary and Neuroendocrinology | ECE2022

Validation of a clinicopathological classification for the prediction of pituitary adenomas: a retrospective cohort study in a PTCOE from 2013 to 2020

Arguello Gordillo Thalia , Miguel Castro Garcia Jose , Martinez Gauffin Lucia , Kuptsov Artem , Tejedo-Flors Dolores , Eugenia Torregrosa-Quesada Maria , Abarca Olivas Javier , Concepcion Luis , Aranda Ignacio , Pico Antonio

Introduction: Because of the increase of brain image explorations, the prevalence of pituitary tumours has increased a lot. Although most of them have an indolent behaviour, some behave aggressively, demanding a lot of resources for their management. Therefore, it is very important to identify them as soon as possible. The recent WHO 2017 classification of pituitary tumours gives insights into improving their identification using the immunostaining (IS) of transcription factor...

ea0081p675 | Pituitary and Neuroendocrinology | ECE2022

Central diabetes insipidus following immunization with BNT162b2 mRNA Covid-19 vaccine

Bouca Bruno , Roldao Marisa , Bogalho Paula , Cerqueira Luis , Silva-Nunes Jose

Introduction: The endocrine complications of COVID-19 remain largely unknown. Cases of central diabetes insipidus (CDI) have been reported after COVID-19, with hypophysitis being the most likely cause. COVID-19 vaccines potential adverse effects may mimetize some of these complications. We present a case of a woman who developed CDI one week after the 2 nd dose of BNT162b2 mRNA COVID-19 vaccine.Case Report: Female patient, 37 years old, with rheumatoid a...

ea0081p676 | Pituitary and Neuroendocrinology | ECE2022

Pheochromocytoma/paraganglioma metastatic potential prediction

Rzepka Ewelina , Kurzyńska Anna , Grochowska Anna , Ulatowska-Białas Magdalena , Skalniak Anna , Lech Martyna , Opalinska Marta , Bogusławska Anna , Przybylik-Mazurek Elwira , Sowa-Staszczak Anna , Gilis-Januszewska Aleksandra , Hubalewska-Dydejczyk Alicja

Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumours, which derive from the chromaffin cells of the adrenal medulla or extra-adrenal sympathetic and parasympathetic ganglia. About 15-20% of those neoplasms could present malignant course. Prediction of PPGL metastatic potential still remains a great clinical challenge, since the sensitivity and specificity of proposed prediction systems are not satisfactory. We performed a retrospective database search for ...

ea0081p677 | Pituitary and Neuroendocrinology | ECE2022

Adrenal haemorrhage in a pheochromocytoma - a rare, life-threatening and challenging complication

Rzepka Ewelina , Kokoszka Joanna , Grochowska Anna , Ulatowska-Białas Magdalena , Lech Martyna , Opalińska Marta , Godlewska Magdalena , Przybylik-Mazurek Elwira , Gilis-Januszewska Aleksandra , Hubalewska-Dydejczyk Alicja

Adrenal haemorrhage is a rare, usually life-threating complication, most commonly connected with primary or metastatic adrenal tumour. Among them pheochromocytoma is the most common cause of spontaneous adrenal bleeding and accounts for nearly 50% of cases. We performed a database search for pheochromocytoma patients, diagnosed and treated in Endocrinology Department, University Hospital in Cracow from 2005 to 2021. 206 patients with pheochromocytoma were identified. Subsequen...

ea0081p678 | Pituitary and Neuroendocrinology | ECE2022

Treatment of cushing’s disease (CD) after primary failure of pituitary surgery or recurrence: evaluation of long-term control by medical treatment

Ghalawinji Adel , Cristante Justine , Lefournier Virginie , Chaffanjon Philippe , muller Marie , Gay Emmanuel , Olivier Chabre

Introduction: Pituitary surgery is the first line treatment for most patients with Cushing’s disease (CD) but after failure or recurrence after surgery 3 main strategies can be proposed: medical treatment (MT), a 2 nd pituitary surgery, bilateral adrenalectomy (BA). Pituitary radiotherapy is a 4th strategy, generally combined with one of the 3 others. Medical treatment (MT) emerges as an attractive strategy but there are little data on long-term control after f...

ea0081p679 | Pituitary and Neuroendocrinology | ECE2022

Efficacy, safety and metabolic impact of long-term pegvisomant therapy in acromegaly: results from a 10-year single center experience

Pirchio Rosa , Simona Auriemma Renata , Elena Montini Maria , Vergura Alice , Pivonello Rosario , Colao Annamaria

Pegvisomant (PEG) is effective in acromegaly control and exerts a positive impact on glucose metabolism. The current study aimed at investigating the effects of 10-years PEG treatment on disease control, pituitary adenoma size, and metabolic profile in patients with acromegaly resistant to somatostatin analogues (SRLs). Twenty-two patients (9 men,13 women, age 45.54 ± 12.83 years) treated with PEG for 10 years, in monotherapy or in combination with SRLs, were included in ...

ea0081p680 | Pituitary and Neuroendocrinology | ECE2022

Long-term pasireotide therapy: real life experience of a single referral center

Pirchio Rosa , Vergura Alice , Elena Montini Maria , Simona Auriemma Renata , Pivonello Rosario , Colao Annamaria

Pasireotide is a second-line therapy for acromegaly, that allows to obtain disease control in patients previously uncontrolled. However, pasireotide-induced hyperglycemia is of major concern. Currently, few data concerning prolonged use of pasireotide are available. The current retrospective study aimed at investigating the efficacy and safety of long-term pasireotide therapy. Sixteen consecutive patients (5 males, 11 females, age 47 ± 11 years) undergoing pasireotide for...

ea0081p681 | Pituitary and Neuroendocrinology | ECE2022

The burden of adult growth hormone deficiency diagnostic tests: results of a patient experience survey in the UK

Lewis Harry , Mumford Joanne , McBride Pat , Whittingham Pauline , Darley Glenn , Chernai Nacima

Objectives: To collect qualitative and quantitative information on the burden of adult growth hormone deficiency (AGHD) diagnostic tests for the patient.Methods: A survey was published on The Pituitary Foundation’s website and social media pages; respondents completed it online using SmartSurvey over period of two months (October-November 2021). 105 respondents took the survey, with 9 screened out after the first question because they had never take...

ea0081p682 | Pituitary and Neuroendocrinology | ECE2022

Berlin questionnaire and epworth sleepiness scale as screening tools of sleep apnea risk in patients with acromegaly: comparison of 144 patients and an age-and gender-matched health cohort

Pirchio Rosa , Addato Raffaele , Elena Montini Maria , Valentina De Santis Ciacci Corina , Vergura Alice , Simona Auriemma Renata , Pivonello Rosario , Colao Annamaria

Sleep apnea (SA) is a common acromegaly comorbidity, influencing patients’ quality of life and mortality risk. Despite its importance, SA frequently remains undiagnosed, and its real prevalence seems to be underestimated. The current observational study aimed at investigating the role of Berlin questionnaire (BQ) and Epworth sleepiness scale (ESS) in assessing the risk of SA in this high-risk population, and to compare the results with an age-and gender-matched health coh...

ea0081p683 | Pituitary and Neuroendocrinology | ECE2022

Pallister-hall syndrome diagnosed in a young man after an acute adrenal crisis

Grassa Anis , Yazidi Meriem , Hadj Sliman Chayma Bel , Khessairi Nadia , Oueslati Ibtissem , Chihaoui Melika

Introduction: Pallister-Hall syndrome (PHS) is a very rare congenital syndrome, and its exact prevalence is still unknown. The clinical diagnosis is usually made when a hypothalamic hamartoma is associated with polydactyly. Endocrine manifestations consist of hypopituitarism, hypopituitarism, which can affect one or more pituitary axes, and precocious puberty. Here, we report the case of an 18-year-old young man in whom the diagnosis of PHS was delayed until his hospitalizatio...

ea0081p684 | Pituitary and Neuroendocrinology | ECE2022

Pituitary macroadenoma revealed by symptoms mimicking Hakim Adams triad

Grassa Anis , Yazidi Meriem , Gharbi Youssef , Oueslati Ibtissem , Chaker Fatma , Chihaoui Melika

Introduction: The clinical presentation of a secretory pituitary macroadenoma usually consists of a tumor syndrome accompanied by visual disturbances with signs of pituitary insufficiency and/or hormonal hypersecretion. Herein we describe an unusual presentation of a mixed secretory adenoma.Observation: A 69-year-old was referred to our department for the management of a pituitary macroadenoma revealed by a symptomatology mimicking the Hakim Adams triad ...

ea0081p685 | Pituitary and Neuroendocrinology | ECE2022

Immunotherapy-induced endocrinopathies: a case report

Dobrovolskytė Radvilė , Panceraite Lina , Prielaidaite Karolina , Semeniene Kristina , Zilaitiene Birute

Endocrinopathies are one of the most common side effects induced by immunotherapy. The side effects result from the activation of immune system, which affects not only cancerous but also healthy body cells. In most cases, only one endocrinopathy occurs, but in our presented case we describe multiple endocrinopathies that occurred to a one person. 53-years-old male patient was referred to the Emergency department due to severe hyperglycemia (37.13 mmol/l) and the following symp...

ea0081p686 | Pituitary and Neuroendocrinology | ECE2022

Ruptured rathke’s cleft cyst (RCC) with irritation of optic apparatus and rapidly evolving panhypopituitarism

Montebello Annalisa , Grieve Joan , J Marcus Hani , Miszkiel Katherine , Valerio Fernanda , Martyn Drake William

Background: Rathke’s cleft cysts (RCC) are benign intrasellar cysts that originate from the remnants of Rathke’s pouch and contain mucoid material. Most are asymptomatic, but some may compress adjacent structures leading to visual disturbances and endocrinopathies.Case Report: A 20-year-old gentleman had an MRI Head in view of headaches. This showed a 17.7 mm peripherally enhancing suprasellar lesion with no intrinsic T1 high signal pre- contra...

ea0081p687 | Pituitary and Neuroendocrinology | ECE2022

Plurihormonal pituitary macroadenoma, co −secreting TSH/GH/and prolactin: a clinical challenge

Bilbao Garay Ismene , Egana Nerea , Perez De Ciriza Maite , Chinchurreta Laura , Elias Cristina , Venegas Inmaculada , Amilibia Ane , Garcia Cristina , Rojo Jorge , Yoldi Alfredo

Background: Co secreting Thyrotropin/growth hormone pituitary adenomas are rare, and their clinical presentation and long term management may be challenging. Clinically, the majority of plurihormonal pituitary adenomas are silent and diagnosis almost always relies on immunohistochemical analysis of the tumor tissue. Early detection is key to optimize patient mamagement. We report a case of pituitary plurihormonal macroadenoma with overt clinical hyperthyroidism and minimal GH ...

ea0081p688 | Pituitary and Neuroendocrinology | ECE2022

Implications of the 2017 WHO classification in the characterization of GH-secreting pituitary tumors

Burcea Iulia Florentina , Nicoleta Nastase Valeria , Raluca Ceausu Amalia , Dumitraşcu Anda , Maria Cimpean Anca , Raica Marius , Poiana Catalina

Introduction: Somatotroph pituitary adenomas (PAs) represent 10-15% of all resected PAs, exhibiting immunohistochemical (IHC) positivity for GH (growth hormone) and PIT-1 transcription factor (TF). The histopathological (HP) and IHC variability of each PA influences the phenotype, radiological features, and therapy response.Materials and methods: The study included 33 patients with acromegaly, with men: women ratio of 17:16. The HP-IHC characteristics we...

ea0081p689 | Pituitary and Neuroendocrinology | ECE2022

Peculiar presentation of a TSH-secreting pituitary adenoma: a possible new multiple endocrine syndrome?

Goggi Giovanni , Campi Irene , Delle Donne Elisa , Moro Mirella , Guizzardi Fabiana , Bonomi Marco , Persani Luca

Introduction: TSH-secreting pituitary adenomas (TSHomas) are a rare cause of central hyperthyroidism, accounting for less than 1% of all pituitary adenomas, with a prevalence in the general population of 1-2 cases per million.Case Presentation: A 45-year-old female patient presented in 2009 with hypertension and tachycardia: blood tests revealed an inappropriately normal TSH with high fT3/fT4 levels and primary hyperaldosteronism. She declined further in...

ea0081p690 | Pituitary and Neuroendocrinology | ECE2022

Clinical characteristics at diagnosis and diagnostic delay among newly-diagnosed patients with acromegaly- single-center, pilot study

Godlewska Magdalena , Bogusławska Anna , Kluczyński Łukasz , Rzepka Ewelina , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Introduction: Diagnostic delay remains significant among the patients with acromegaly, even though the disease awareness has improved over the years.Aim: The aim was to investigate the diagnostic delay and symptoms present at diagnosis of acromegaly among the newly-diagnosed patients.Material and methods: 72 consecutive patients diagnosed with acromegaly between 01.2014 and 12.2021 were evaluated. Division into groups based on: gen...

ea0081p691 | Pituitary and Neuroendocrinology | ECE2022

Very-low-calorie-ketogenic-diet (VLCKD) approach to manage obesity in craniopharingioma patients

Ruxandra Cotta Oana , Alessi Ylenia , Certo Rosaria , Piccione Alessandra , Casablanca Rosalinda , Paola Giuseppe , Buda Martina , Scaramuzzo Monica , Ferrau' Francesco , Cannavo' Salvatore

Background: Craniopharingioma patients frequently experience severe obesity, unresponsive to caloric restriction or lifestyle modifications. Recently very-low-ketogenic-diets (VLCKD) proved to be a promising lifestyle intervention for obesity management, but no data are available regarding their effect on hypothalamic obesity (HO).Introduction: We present the outcome of VLCKD protocol applied in young patients with HO following neurosurgery for craniopha...

ea0081p692 | Pituitary and Neuroendocrinology | ECE2022

Analysis of the frequency of relapses according to the national registry cushing’ s syndrome in Republic of Uzbekistan

Mirsaidova Umida A. , Khalimova Zamira

Transsphenoidal pituitary surgery is the method of choice in the treatment of ACTH-DCS, although to date, according to a number of researchers, the method is not ideal. Despite the achievement of immediate postoperative remission in 69-98% of cases, with an increase in the duration of follow-up after TSS from 5 to 10 years, an increase in the frequency of relapses from 15 to 66% is observed. In this regard, we analyzed cases of ACTH DCS subjected to TSS for 2003-2021, included...

ea0081p693 | Pituitary and Neuroendocrinology | ECE2022

Multimodal treatment including temozolomide (TMZ) and pasireotide for aggressive, giant silent corticotroph PiTNET in a young patient

Bogusławska Anna , Kluczyński Łukasz , Godlewska Magdalena , Rzepka Ewelina , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Silent corticotroph pituitary neuroendocrine tumours (PiTNETs) are a subtype of nonfunctioning PiTNETs, that present positive immunostaining for adrenocorticotropin (ACTH) and/or show the expression of the transcription factor T-PIT without clinical signs of hypercortisolemia. They constitute 20% of all corticotroph PitNETs and manifest in most cases as macroadenoma with suprasellar extension and a higher tendency to apoplexy. We present a 33-year-old male with aggressive cour...

ea0081p694 | Pituitary and Neuroendocrinology | ECE2022

Radiological classification of craniopharyngioma based on its origin

Skoric Polovina Tanja , Ozretic David , Solak Mirsala , Kraljevic Ivana , Dusek Tina , Balasko Annemarie , Zibar Tomšić Karin , Kastelan Darko

Recognizing the site of origin of craniopharyngioma (CP) along the hypothalamus-pituitary axis according to pre-operative MR is helpful to understand its growth pattern in relation to hypothalamus, which is critical in the prediction of hypothalamic injury and planning of treatment. We retrospectively classified 29 CP according to MR pre-operative image study using modified classification of Tang et al. (Nature, 8:10215, 2018). According to its relation to pituitary s...